N
NanoDx
Medical device company developing breakthrough point-of-care diagnostic solutions
About NanoDx
NanoDiagnostics operates in the healthcare diagnostics market, specializing in real-time, point-of-care diagnostic solutions. The company's core product, the NanoDxTM System, provides rapid and accurate test results from finger stick blood or saliva samples in less than 2 minutes. This system aims to offer definitive assessments to avoid misdiagnoses, particularly for conditions such as traumatic brain injuries (TBI). NanoDiagnostics serves hospitals, emergency rooms, and healthcare providers who require quick and reliable diagnostic tools to improve patient outcomes and streamline workflows. The business model revolves around selling the NanoDxTM System to healthcare facilities, thereby generating revenue through the sale of diagnostic equipment and related services. The company addresses a significant market need, as traditional diagnostic methods can be time-consuming, expensive, and often inaccurate. By offering a cost-effective and efficient alternative, NanoDiagnostics aims to reduce the global economic burden of TBI, which is estimated at $400 billion annually.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Southborough, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 32.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Point of Care, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jul 2020 | $18M | $72M | Shepherd Kaplan | — |
| EARLY VC✓Equity / VC | Nov 2019 | $6M | $24M | Undisclosed | — |
Growth signals
Latest recorded traffic for NanoDx is 1.3K monthly website visits, up 30% over the last three months. NanoDx's team declined 8.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Provident Healthcare Partners
Series B and later1 investor entered at this stage
Shepherd Kaplan
Other known investors2 additional known investors
Harvard University
MedScience Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NanoDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NanoDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.